Continuous Glucose Monitoring Device Market Size, Share, and Trends 2024 to 2034

The continuous glucose monitoring device market size estimated at USD 5.74 billion in 2025 and is anticipated to reach around USD 10.65 billion by 2034, expanding at a CAGR of 7% from 2025 to 2034. The North America continuous glucose monitoring device market size reached USD 2.20 billion in 2024 and is expanding at a CAGR of 7.04% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : January 2025
  • Report Code : 1374
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Continuous Glucose Monitoring (CGM) Device Market 

5.1. COVID-19 Landscape: Continuous Glucose Monitoring (CGM) Device Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Continuous Glucose Monitoring (CGM) Device Market, By Component

8.1. Continuous Glucose Monitoring (CGM) Device Market, by Component Type,

8.1.1. Transmitters

8.1.1.1. Market Revenue and Forecast

8.1.2. Receivers

8.1.2.1. Market Revenue and Forecast

8.1.3. Sensors

8.1.3.1. Market Revenue and Forecast

8.1.4. Integrated Insulin Pumps

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Continuous Glucose Monitoring (CGM) Device Market, By End User

9.1. Continuous Glucose Monitoring (CGM) Device Market, by End User,

9.1.1. Hospitals

9.1.1.1. Market Revenue and Forecast

9.1.2. Home Healthcare

9.1.2.1. Market Revenue and Forecast

9.1.3. Others

9.1.3.1. Market Revenue and Forecast

Chapter 10. Global Continuous Glucose Monitoring (CGM) Device Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Component

10.1.2. Market Revenue and Forecast, by End User

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Component

10.1.3.2. Market Revenue and Forecast, by End User

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Component

10.1.4.2. Market Revenue and Forecast, by End User

10.2. Europe

10.2.1. Market Revenue and Forecast, by Component

10.2.2. Market Revenue and Forecast, by End User

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Component

10.2.3.2. Market Revenue and Forecast, by End User

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Component

10.2.4.2. Market Revenue and Forecast, by End User

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Component

10.2.5.2. Market Revenue and Forecast, by End User

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Component

10.2.6.2. Market Revenue and Forecast, by End User

10.3. APAC

10.3.1. Market Revenue and Forecast, by Component

10.3.2. Market Revenue and Forecast, by End User

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Component

10.3.3.2. Market Revenue and Forecast, by End User

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Component

10.3.4.2. Market Revenue and Forecast, by End User

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Component

10.3.5.2. Market Revenue and Forecast, by End User

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Component

10.3.6.2. Market Revenue and Forecast, by End User

10.4. MEA

10.4.1. Market Revenue and Forecast, by Component

10.4.2. Market Revenue and Forecast, by End User

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Component

10.4.3.2. Market Revenue and Forecast, by End User

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Component

10.4.4.2. Market Revenue and Forecast, by End User

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Component

10.4.5.2. Market Revenue and Forecast, by End User

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Component

10.4.6.2. Market Revenue and Forecast, by End User

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Component

10.5.2. Market Revenue and Forecast, by End User

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Component

10.5.3.2. Market Revenue and Forecast, by End User

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Component

10.5.4.2. Market Revenue and Forecast, by End User

Chapter 11. Company Profiles

11.1. Abbott Laboratories

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Dexcom, Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. A. Menarini Diagnostics

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Echo Therapeutics, Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. GlySens Incorporated

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Johnson & Johnson

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Medtronic plc

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Senseonics Holdings, Inc.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. F. Hoffmann-La Roche Ltd

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Ypsomed

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global continuous glucose monitoring device market size was reached at USD 5.36 billion in 2024 and is projected to hit USD 10.65 billion by 2034.

The increasing awareness regarding the diabetes coupled with the growing prevalence of diabetes among the population is driving the growth of the continuous blood glucose monitoring device market.

The global continuous glucose monitoring device market is growing at a CAGR of 7% over the forecast period 2025 to 2034.

The major players operating in the continuous glucose monitoring device market are Abbott Laboratories, Dexcom, Inc., A. Menarini Diagnostics, Echo Therapeutics, Inc., GlySens Incorporated, Johnson & Johnson, Medtronic plc, Senseonics Holdings, Inc., F. Hoffmann-La Roche Ltd, Ypsomed

The North America region accounted for around 39% of the market share in 2024 and will lead the market in near future.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client